1 for each dose vs placebo group comparison in
post hoc analysis).
2 nt mild bleeding or any severe bleeding in a
post hoc analysis.
3 s intermediate between the two groups in the
post hoc analysis.
4 h specificity (87%) and sensitivity (78%) in
post hoc analysis.
5 t tests and analysis of variance with Tukey
post hoc analysis.
6 reatment with azithromycin in an exploratory
post hoc analysis.
7 tial outcome predictors were identified in a
post hoc analysis.
8 ns and all-cause mortality was assessed in a
post hoc analysis.
9 o- or hyper-methylated locus without further
post-hoc analysis.
10 ACITY 006, and ASCEND) were included in this
post-hoc analysis.
11 MSC viability was tested in a
post-hoc analysis.
12 CI], 0.09 to 0.59; P = 0.002; relative risk [
post hoc analysis],
0.37; 95% CI, 0.16 to 0.84; P = 0.02
13 In a
post hoc analysis,
192/885 (22%) children developed dela
14 In a
post hoc analysis,
a cut-off value of CFT for systemic t
15 In addition, from
post hoc analysis,
a greater proportion of brolucizumab-
16 We did a
post-hoc analysis after complete ICS withdrawal (months
17 In a
post hoc analysis,
an approximately 4-fold difference wa
18 The present
post hoc analysis assessed the end point of all-cause mo
19 Post hoc analysis,
between-study differences in patient
20 Post hoc analysis by age group showed improved survival
21 In this
post-hoc analysis,
Cap-assisted colonoscopy is a safe te
22 In
post hoc analysis,
clinic visits significantly increased
23 This
post hoc analysis combines the pre-specified subgroups o
24 0.04) were associated with RV dysfunction on
post hoc analysis.
Conclusions: RV dysfunction is associa
25 The
post hoc analysis confirmed these results and also showe
26 This
post hoc analysis demonstrated greater potassium and cre
27 Post hoc analysis demonstrated significant differences i
28 A
post hoc analysis demonstrated that simvastatin therapy
29 This
post hoc analysis demonstrated the visual outcome benefi
30 In
post hoc analysis,
detectable plasma dipyridamole levels
31 Post hoc analysis did not detect any significant differe
32 This
post hoc analysis evaluated 3 patient groups from ATTAIN
33 This
post hoc analysis evaluated the influence of select base
34 Post hoc analysis;
examination of nonrandomized subsets
35 This
post hoc analysis examined potential interaction between
36 This hypothesis-generating
post hoc analysis examined the efficacy of eribulin acco
37 This
post hoc analysis examined whether the effects of the SB
38 A
post hoc analysis (
excluding data for 20 patients from t
39 A
post hoc analysis exploring the effect of atrophy in the
40 by using a one-way analysis of variance with
post hoc analysis for statistically significant differen
41 A
post hoc analysis for the primary end point considering
42 e interval: 1.02-5.24; P = .045), based on a
post-hoc analysis for the modified definition.
43 A
post hoc analysis found nine (43%) patients in the activ
44 A
post hoc analysis found that, compared to patients with
45 In a
post hoc analysis from 10 ODYSSEY trials, greater percen
46 Post hoc analysis from a phase III randomized controlled
47 in relation to 90-day clinical outcomes as a
post hoc analysis from a prospective multicentre observa
48 This is
post hoc analysis from the Clopidogrel for High Atheroth
49 This
post hoc analysis from the EUCLID trial (Examining Use o
50 urgery for left main disease by performing a
post hoc analysis from the multicenter, randomized EXCEL
51 d vaccine in young women, were combined in a
post-hoc analysis (
GlaxoSmithKline [GSK] e-track number
52 In a
post hoc analysis,
HFpEF patients with LV hypertrophy (n
53 In a
post hoc analysis,
higher rates of HIV-1 protection were
54 hospital admission for heart failure in the
post hoc analysis (
HR 1.00, 95% CI 0.82-1.21) and result
55 unity-matched controls were included in this
post-hoc analysis if their mid-upper arm circumference h
56 Here, in a
post hoc analysis in 1147 patients with type 2 diabetes
57 We also performed a
post hoc analysis in which the rates of major complicati
58 In a
post hoc analysis,
in patients with symptomatic recurren
59 This
post-hoc analysis included 1,030 participants in the Ger
60 However, in a
post hoc analysis,
losartan was associated with improved
61 In a
post-hoc analysis,
mean reductions in LDL cholesterol in
62 In this
post hoc analysis,
mortality steadily increased with inc
63 hs were obtained from the Protocol T 24-week
post hoc analysis (
n = 546).
64 ed; poor mental health) were examined in the
post-hoc analysis (
n = 74, 34 CBT and 40 controls), CBT
65 view is meant to allow readers to appreciate
post hoc analysis not as an entity with a single approac
66 Post hoc analysis of (68)Ga-PSMA-11 PET/CT implied a maj
67 evidence from 1 RCT of 21 162 patients and a
post hoc analysis of 1 RCT of 15 603 patients to answer:
68 AF and long-term risk of CVA by performing a
post hoc analysis of 10-year outcomes of the ART (Arteri
69 This was a
post hoc analysis of 130 prospectively included patients
70 Post hoc analysis of 2 antiviral studies was performed.
71 Post hoc analysis of 2 prospectively followed up pediatr
72 We undertook a
post hoc analysis of 2 randomized clinical trials evalua
73 Post hoc analysis of 2 similarly designed phase 3 trials
74 We performed a
post hoc analysis of 30 participants of a clinical trial
75 We performed a
post hoc analysis of 561 HIV-infected sputum-expectorati
76 A
post hoc analysis of 637 cultures from 610 medical patie
77 This
post hoc analysis of a clinical trial assessed the medic
78 This investigation was a
post hoc analysis of a cohort in the e-ROP Study (a mult
79 In this
post hoc analysis of a large placebo-controlled randomiz
80 In a
post hoc analysis of a multicenter randomized controlled
81 We performed a
post hoc analysis of a phase III placebo-controlled stud
82 In this
post hoc analysis of a prematurely terminated randomized
83 This was a
post hoc analysis of a prospective cohort of critically
84 tion on the outcome of 30-day mortality in a
post hoc analysis of a prospective cohort study of patie
85 The present study is a
post hoc analysis of a prospective trial which randomize
86 This was a
post hoc analysis of a prospectively collected cohort of
87 We performed a
post hoc analysis of a published prospective multicenter
88 In this
post hoc analysis of a randomized clinical trial which t
89 We performed a
post hoc analysis of a randomized controlled trial of no
90 We performed a
post hoc analysis of a randomized controlled trial of tw
91 HV-6B reactivation after allogeneic HCT in a
post hoc analysis of a randomized controlled trial.
92 Study 3 was a
post hoc analysis of a randomized trial of inhaled aztre
93 ed for treatment of endovascular stroke in a
post hoc analysis of a recent randomized controlled tria
94 A
post hoc analysis of a retrospective cohort including di
95 This investigation was a
post hoc analysis of a subgroup of laser control eyes in
96 , and Participants: This investigation was a
post hoc analysis of a subgroup of laser control eyes in
97 This was a
post hoc analysis of all eyes in the PIONEER undergoing
98 A
post hoc analysis of all pathologic reports from patient
99 This was a
post hoc analysis of an intention-to-treat population of
100 A meta-analysis and a
post hoc analysis of an RCT in patients with stable card
101 In a
post hoc analysis of ARISTOTLE (Apixaban for Reduction i
102 Post hoc analysis of baseline patient characteristics in
103 ne the origin of lactate.Methods: This was a
post hoc analysis of baseline variables of 1,741 patient
104 In a
post hoc analysis of children weighing 65 kg or less, th
105 Post hoc analysis of clinical and laboratory features co
106 A
post hoc analysis of clinical trials of adults with acti
107 l Coherence Tomography, seems to emerge from
post hoc analysis of collected data demonstrating strong
108 In a
post hoc analysis of data collected for prospective obse
109 We performed a
post hoc analysis of data from a phase 2 trial to assess
110 In a
post hoc analysis of data from a phase III study of the
111 ional review board approval was obtained for
post hoc analysis of data from a prospective single-cent
112 Post hoc analysis of data from HARBOR was undertaken.
113 We conducted a
post hoc analysis of data from pilot D-Health, which is
114 Post hoc analysis of data from the 36-month prospective,
115 Post hoc analysis of data from the inception cohort asse
116 In this
post hoc analysis of data from the Physical Activity and
117 We conducted a
post hoc analysis of data from the TEMPO 3:4 trial.
118 A
post hoc analysis of data from two studies was performed
119 Post hoc analysis of efficacy, safety, and resource util
120 This randomized trial report is based on a
post hoc analysis of extended follow-up beyond that of t
121 This was a
post hoc analysis of eyes in the DISCOVER study undergoi
122 We performed a
post hoc analysis of FIGHT to investigate whether liragl
123 l analyses were conducted using ANOVA with a
post hoc analysis of Fisher's LSD.
124 Post hoc analysis of functionally connected pairs sugges
125 Post hoc analysis of gene array data demonstrated signif
126 We conducted a
post hoc analysis of HF-related MACE (HF hospitalization
127 Post hoc analysis of inflammatory and nutritional biomar
128 We performed a prespecified
post hoc analysis of ischemic stroke patients screened f
129 A
post hoc analysis of Medicare Part D data revealed low p
130 In this
post hoc analysis of PARAGON-HF (Prospective Comparison
131 An exploratory
post hoc analysis of participants with a consistent rate
132 We performed a
post hoc analysis of patients enrolled in the DIVA (Drug
133 This is a
post hoc analysis of patients enrolled in the Rituximab
134 In a
post hoc analysis of patients with an initially abnormal
135 This
post hoc analysis of phase 3 data further investigated t
136 Post hoc analysis of prospectively collected data.
137 post hoc analysis of risk factors associated with arthri
138 In this
post hoc analysis of ROSE AHF, the response to vasoactiv
139 In a
post hoc analysis of samples from an intrapartum azithro
140 In a
post hoc analysis of SPRINT, we defined change in eGFR a
141 In a
post hoc analysis of subjects with an estimated glomerul
142 from a recent randomized controlled trial, a
post hoc analysis of that trial, a meta-analysis, and a
143 or BITA grafts and outcomes by performing a
post hoc analysis of the ART.
144 We performed a
post hoc analysis of the Assessment of Dual Antiplatelet
145 A
post hoc analysis of the combined data sets showed that
146 In a
post hoc analysis of the Community-Acquired Pneumonia (C
147 Methods In this
post hoc analysis of the DANISH trial (Danish Study to A
148 Conclusions In this
post hoc analysis of the DANISH trial, ICD therapy was a
149 In this
post hoc analysis of the DEFUSE 2 study, 35 patients wit
150 This was a
post hoc analysis of the Edaravone Phase III Study MCI18
151 CKD progression in children, we performed a
post hoc analysis of the Effect of Strict Blood Pressure
152 We conducted a
post hoc analysis of the Folic Acid for Vascular Outcome
153 We performed a
post hoc analysis of the FOURIER trial (Further Cardiova
154 ients with different ACS phenotypes.Methods:
Post hoc analysis of the ISAACC (Continuous Positive Air
155 This secondary
post hoc analysis of the MAGIC trial included participan
156 nostic factor for overall survival (OS) in a
post hoc analysis of the Mainsail trial.
157 We performed a
post hoc analysis of the METOCARD-CNIC (effect of METOpr
158 Post hoc analysis of the multicenter TTM-trial.
159 unication in advanced cancer, we conducted a
post hoc analysis of the patient intervention component,
160 This is a
post hoc analysis of the PermiT (Permissive Underfeeding
161 Moreover, a
post hoc analysis of the phase 2 trial of NP001 using th
162 Post hoc analysis of the phase 3 VISTA study in patients
163 Post hoc analysis of the phase III RIDE and RISE studies
164 ncluding 50 patients with dose escalation by
post hoc analysis of the phase III trial of rupatadine f
165 mary prevention of atrial fibrillation, this
post hoc analysis of the PREDIMED trial suggests that ex
166 This is a
post hoc analysis of the RE-LY trial.
167 uncontrolled retrospective case series and a
post hoc analysis of the registration trial for temozolo
168 Cross-sectional
post hoc analysis of the Singapore Epidemiology of Eye D
169 In this
post hoc analysis of the Singapore Epidemiology of Eye D
170 Conclusion This
post hoc analysis of the single-center SIESTA trial reve
171 on monitoring for HIV-TB coinfected patients.
Post hoc analysis of the Starting Antiretroviral Therapy
172 weight and follow-up visits and performed a
post hoc analysis of the Treating to New Targets trial,
173 This
post hoc analysis of the trial data aims to investigate
174 We conducted a
post hoc analysis of the vandetanib phase III trial invo
175 A
post hoc analysis of the VISUAL-1 and VISUAL-2 placebo-c
176 In a
post hoc analysis of this dominant subgroup, 6-week mort
177 We report a
post hoc analysis of this trial after a median follow-up
178 We here report a
post hoc analysis of this trial after a median follow-up
179 However, a Bayesian
post hoc analysis of this trial and a subsequent meta-an
180 The
post hoc analysis of time-specific measurements sheds li
181 A
post-hoc analysis of 637 cultures from 610 medical patie
182 Post-hoc analysis of a prospective clinical study.
183 In a
post-hoc analysis of a prospective study, EPAGE criteria
184 Post-hoc analysis of all CYD14/15 trial participants rev
185 We did a
post-hoc analysis of BIOSTAT-CHF, a prospective study in
186 In this report, we did a
post-hoc analysis of cardiovascular and renal outcomes o
187 We conducted a
post-hoc analysis of data from the CANagliflozin cardioV
188 A
post-hoc analysis of data from trial of patients with NA
189 We did a
post-hoc analysis of data from two replicate, randomised
190 We did a
post-hoc analysis of data, which was completed on Sept 2
191 In this
post-hoc analysis of midnasal pneumococcal carriage in a
192 ied subgroup analysis in August, 2013, and a
post-hoc analysis of non-inferiority and safety in March
193 Post-hoc analysis of patients who underwent pancreatoduo
194 In this
post-hoc analysis of pooled MODIFY I/II data, efficacy e
195 Post-hoc analysis of survival to combined endpoint in SM
196 We did a
post-hoc analysis of the 3 year inhaled Steroid Treatmen
197 Post-hoc analysis of the assessments with Tukey's honest
198 We did a
post-hoc analysis of the coaching-based implementation o
199 In a
post-hoc analysis of the PARADIGM-HF trial, we included
200 However, in a
post-hoc analysis of the primary endpoint, the within-tr
201 In a
post-hoc analysis of the whole study population, of thos
202 This is a retrospective
post-hoc analysis of the YELLOW II trial, comparing pati
203 We conducted
post-hoc analysis of two randomized trials including 685
204 This was a
post-hoc analysis of Women's Health Initiative participa
205 We conducted a
post hoc analysis on 1,047 patients with PDD from 2 rand
206 low back pain and/or leg pain and performed
post hoc analysis on changes in opioid dosage 12 months
207 In this
post hoc analysis,
patients in SAVOR-TIMI 53 (Saxaglipti
208 In this
post hoc analysis,
patients with a GRACE score >140 were
209 In this
post hoc analysis,
poor platelet recovery was associated
210 This
post hoc analysis provided additional evidence for the r
211 In a
post-hoc analysis,
rates of patients with inappropriate
212 In a
post-hoc analysis,
reduction of mortality was more evide
213 A
post hoc analysis revealed a more complex picture where
214 However,
post hoc analysis revealed a significant survival benefi
215 Post hoc analysis revealed clear CD in most of these eye
216 patients with moderate negative symptoms, a
post hoc analysis revealed significant improvement of ne
217 Post hoc analysis revealed that, relative to controls, p
218 Post hoc analysis revealed this association is sex speci
219 th contemporaneous psychotomimetic symptoms;
post-hoc analysis revealed that ketamine was the predomi
220 Post-hoc analysis revealed that the effect of DRS model
221 This
post hoc analysis reveals that treatment with denosumab
222 In
post hoc analysis,
right ventricular stroke volume incre
223 roflumilast improved lung function, and in a
post hoc analysis roflumilast significantly reduced the
224 c treatment was determined at 215.5 mum in a
post hoc analysis (
sensitivity 62.5 %, specificity 96.4
225 A
post hoc analysis showed a higher rate of relapse for pa
226 However, a
post hoc analysis showed evidence of effect modification
227 Post hoc analysis showed that KOM had higher SBP than KO
228 Post hoc analysis showed that the effect was greater in
229 A
post hoc analysis showed that this association reflected
230 al, which included heterogeneous patients, a
post-hoc analysis showed significantly worse overall sur
231 Post-hoc analysis showed that the T1/2 of gastric emptyi
232 Post hoc analysis,
small sample size, and examination of
233 In
post hoc analysis,
State-Trait Anxiety Inventory State g
234 In a
post hoc analysis,
stent length was the only subgroup of
235 In a
post hoc analysis,
subjects who received an average dose
236 These results, confirmed by a
post hoc analysis,
suggest that uncertainty is introduce
237 Post hoc analysis suggested an increased risk for recurr
238 Post hoc analysis suggested that like the 22q11DS group,
239 noninferiority analysis was indeterminate, a
post hoc analysis suggested that VA improvement with thi
240 Post hoc analysis suggests a possible association betwee
241 This
post hoc analysis suggests that adalimumab is associated
242 Importantly, this
post hoc analysis supports the notion that patients with
243 In ITT-IS (
post-hoc analysis),
the latter was statistically signifi
244 In a
post hoc analysis,
the 2-year cumulative incidence of he
245 tish COmputed Tomography of the HEART Trial)
post hoc analysis,
the presence of adverse plaque (posit
246 In a
post hoc analysis,
the proportion of IFN-switch patients
247 In a
post hoc analysis,
the rate of major adverse cardiovascu
248 In a
post hoc analysis,
the relationship between average on-t
249 In a
post hoc analysis,
there was evidence of a reduction in
250 In a
post hoc analysis,
there was strong evidence that solar
251 By a
post hoc analysis,
there were no statistically significa
252 We conducted a
post hoc analysis to assess the effect of coadministrati
253 precise locations in time and space and use
post hoc analysis to determine behavioral responses to s
254 We performed a
post hoc analysis to determine whether there was a sex d
255 A
post hoc analysis to discern sources of inter-individual
256 We conducted a
post hoc analysis to explore the potential efficacy of s
257 We did a
post-hoc analysis to analyse patterns of recurrence with
258 In a
post-hoc analysis to compare statins, we combined data f
259 This
post hoc analysis used data from 291 patients treated wi
260 CI, 10% to 37%) by Kaplan-Meier estimate in
post hoc analysis using definitions and methods consiste
261 CI, 7% to 26%) by Kaplan-Meier estimate in a
post hoc analysis using methods consistent with historic
262 In
post hoc analysis using period-wise baselines, supine SV
263 In
post hoc analysis using unique pathogens typed by pulsed
264 In
post hoc analysis,
video laryngoscopy was associated wit
265 ) in G eyes with normal PSD(C24-2) values, a
post hoc analysis was combined with a CD reference stand
266 This exploratory
post hoc analysis was conducted between October 1, 2011,
267 was conducted from 1998 to 2006; the present
post hoc analysis was conducted from March 1, 2014, to M
268 Post hoc analysis was conducted of prospectively collect
269 A
post hoc analysis was conducted with the patients with A
270 A
post hoc analysis was performed for delayed anemia, defi
271 A
post hoc analysis was performed of 496 patients enrolled
272 A
post hoc analysis was performed of a double-blind, rando
273 Post hoc analysis was performed of a previously conducte
274 A
post hoc analysis was performed of the Efficacy of Vasop
275 A
post hoc analysis was performed of the phase 2 trial of
276 A
post hoc analysis was performed on 721 subjects (age, 68
277 A
post hoc analysis was performed on a prospective, multic
278 A
post hoc analysis was performed to assess whether these
279 A
post hoc analysis was performed to determine whether uri
280 The aim of this
post hoc analysis was to assess the occurrence of all (f
281 The aim of this
post hoc analysis was to evaluate sex-specific differenc
282 In a
post hoc analysis,
we also compared results to the EFS r
283 In a
post hoc analysis,
we also compared TSPO availability be
284 In this exploratory
post hoc analysis,
we analyzed patients taking an antide
285 In this
post hoc analysis,
we assessed the association of baseli
286 In a
post hoc analysis,
we compared the risk of 3 composite b
287 In this
post hoc analysis,
we investigated the relationship betw
288 In a
post hoc analysis,
we performed a cross-sectional observ
289 In a
post-hoc analysis,
we also investigated the effects on g
290 In this
post-hoc analysis,
we analysed complete clinical respons
291 In a
post-hoc analysis,
we analysed survival at 7 days after
292 In a
post-hoc analysis,
we found difference in blood pressure
293 In this
post-hoc analysis,
we test the hypothesis that the overa
294 ng Cox proportional hazard models, and, in a
post-hoc analysis,
we used logistic regression models to
295 In this
post-hoc analysis,
we used prospectively collected data
296 In this
post hoc analysis,
weight change at 12 and 24 months was
297 ears of follow-up data were included in this
post hoc analysis,
which was based on a cohort of 100 di
298 We performed an exploratory,
post hoc analysis with 1255 participants (677 men and 57
299 Post-hoc analysis with Bonferroni correction revealed th
300 Post hoc analysis within a randomized trial, the Startin